Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NasalGuard is a topical, non-systemic electrostatic gel designed to prevent the inhalation of airborne particles, including allergens (pollen, pet dander, dust mites), pollutants, and pathogens (viruses and bacteria). Developed by Trutek Corp, the product is applied as a thin layer around the nostrils and above the upper lip. It functions by creating a localized electrostatic field with a positive charge that attracts and traps negatively charged airborne particles, or repels similarly charged ones, before they can enter the nasal passages. This physical barrier mechanism helps reduce the viral or allergen load reaching the respiratory system, making it a preventative tool for allergic rhinitis and respiratory infections. As a drug-free and non-invasive formulation, it is often regulated as a medical device rather than a pharmacological agent.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on NasalGuard.